QRxPharma Ltd.
100 Walker Street
Level 11, Suite 1
North Sydney
NSW 2060
Tel: 61-2-8404-4139
Fax: 61-2-8920-0314
Website: http://www.qrxpharma.com/
69 articles about QRxPharma Ltd.
-
QRxPharma Ltd.: ASX Preliminary Final Report – 2014 Financial Year
8/28/2014
-
QRxPharma Ltd. Provides Feedback On End-of-Review Meeting With The FDA On Moxduo®
7/11/2014
-
QRxPharma Ltd. Receives Complete Response Letter From FDA Regarding Moxduo® NDA
5/27/2014
-
QRxPharma Ltd. COO Promoted To Top Post
5/2/2014
-
QRxPharma Ltd. Fails To Win Panel Backing For New Painkiller Moxduo
4/23/2014
-
QRxPharma Pty Ltd. Completes A$11.6 Million Capital Raising
12/13/2013
-
QRxPharma Pty Ltd. Announces 25 May 2014 As New PDUFA Date For MOXDUO® NDA
12/11/2013
-
QRxPharma Pty Ltd. Refiles MOXDUO® New Drug Application With The FDA
11/26/2013
-
QRxPharma Pty Ltd. Announces Successful Completion Of A$7.5 Million Placement
11/13/2013
-
QRxPharma Pty Ltd. Reports Positive Meeting With the FDA on MOXDUO®
10/9/2013
-
QRxPharma Pty Ltd. Announces MOXDUO® License With Aspen
9/11/2013
-
QRxPharma Pty Ltd. Scores a Date With the FDA Regarding MOXDUO® NDA
9/6/2013
-
QRxPharma Pty Ltd. Receives Complete Response Letter From FDA Regarding MOXDUO® NDA
8/28/2013
-
Aesica Announces Collaboration With QRxPharma Pty Ltd. for the Worldwide Promotion of Stealth Beadlets® Abuse Deterrence Technology
7/22/2013
-
QRxPharma Pty Ltd. Updates MOXDUO® NDA Review
6/26/2013
-
QRxPharma Pty Ltd. Granted US Patent on Hybrid Opioids
6/12/2013
-
QRxPharma Pty Ltd. Sets PDUFA Date for MOXDUO® NDA
3/14/2013
-
QRxPharma Pty Ltd. Resubmits MOXDUO® New Drug Application to the FDA
2/28/2013
-
QRxPharma Pty Ltd. and FDA Establish Path Forward for Resubmission of MOXDUO® New Drug Application
1/16/2013
-
Paladin Labs Inc. Announces Agreement With QRxPharma Pty Ltd. for Up to $25 Million
10/10/2012